Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Axsome Therapeutics, Inc. (AXSM)

70.27   -1.23 (-1.72%) 01-27 16:00
Open: 71.29 Pre. Close: 71.5
High: 72.93 Low: 69.21
Volume: 718,908 Market Cap: 3,052(M)

Technical analysis

as of: 2023-01-27 4:42:44 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 92.15     One year: 107.63
Support: Support1: 67.1    Support2: 59.81
Resistance: Resistance1: 78.9    Resistance2: 92.15
Pivot: 68.17
Moving Average: MA(5): 71.26     MA(20): 69.59
MA(100): 60.56     MA(250): 46.11
MACD: MACD(12,26): 0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 79     %D(3): 75.8
RSI: RSI(14): 50.4
52-week: High: 82  Low: 20.62
Average Vol(K): 3-Month: 1,354 (K)  10-Days: 823 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ AXSM ] has closed below upper band by 34.1%. Bollinger Bands are 27.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 72.96 - 73.45 73.45 - 73.86
Low: 68.3 - 68.76 68.76 - 69.15
Close: 69.58 - 70.34 70.34 - 70.97

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Headline News

Sat, 28 Jan 2023
DekaBank Deutsche Girozentrale sells 10,000 Axsome ... - Best Stocks

Fri, 27 Jan 2023
Brinker Capital Investments LLC Invests $267000 in Axsome ... - MarketBeat

Mon, 23 Jan 2023
AXSM April 21st Options Begin Trading - Nasdaq

Fri, 20 Jan 2023
Is Axsome Therapeutics Inc (AXSM) a Smart Choice in Biotechnology Friday? - InvestorsObserver

Thu, 19 Jan 2023
3 Unstoppable Stocks to Keep Buying in 2023 - The Motley Fool

Mon, 09 Jan 2023
$100 Invested In This Stock 5 Years Ago Would Be Worth $1,900 Today - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 43 (M)
Shares Float 35 (M)
% Held by Insiders 18.4 (%)
% Held by Institutions 61.7 (%)
Shares Short 7,370 (K)
Shares Short P.Month 6,790 (K)

Stock Financials

EPS -3.73
EPS Est Next Qtl -0.35
EPS Est This Year -1.38
EPS Est Next Year -0.92
Book Value (p.s.) 3.61
Profit Margin (%) 0
Operating Margin (%) -591.5
Return on Assets (ttm) -41.7
Return on Equity (ttm) -159.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0.59
EBITDA (p.s.) -3.44
Qtrly Earnings Growth 0
Operating Cash Flow -118 (M)
Levered Free Cash Flow -50 (M)

Stock Valuations

PE Ratio -18.89
PEG Ratio 0.3
Price to Book value 19.41
Price to Sales 118.88
Price to Cash Flow -25.91

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.